UNSPSC 51285702: Tolfamide

This classification denotes an enzyme inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7TJT8X832U. European Medicines Agency schedules Tolfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11154MIG. Tolfamide generally arises in the molecular formula C8H12N3O2P.

The term TOLFAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 35, no. 5 1981, list 21.) TOLFAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 51285702 Tolfamide is a Commodity code that nominally designates a specific pharmaceutical product, but recent state and local opportunities tagged under it span pharmaceutical procurement more broadly—naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and therapeutic pharmacy initiatives—rather than tolfamide specifically. State and local buyers under this code include county health departments, state health and human services commissions, municipal fire departments, and cooperative purchasing alliances serving multi-state government networks. The actual solicitations reflect procurement of emergency medical supplies, generic pharmaceuticals through authorized wholesaler networks, and pharmacy benefit program infrastructure rather than a single active pharmaceutical ingredient. Issuing bodies range from single-jurisdiction county and city purchasing offices to large multi-state cooperative purchasing vehicles that aggregate demand across participating jurisdictions.

Recent activity spans multiple states and procurement mechanisms. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers and demonstrating cGMP and Drug Supply Chain Security Act compliance. Seminole County, Florida issued an IFB (posted June 30, 2026, due July 26, 2023—note discrepant dates in source) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building and a two-year initial term with one-year renewal option. The City of Tampa issued an IFB on March 25, 2026 (due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, estimated at $700,000, with a one-year award period and optional two additional one-year renewals, designated as a sheltered market procurement for certified Small Local Business Enterprises. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization arrangements. The code shows activity primarily in Florida, Texas, and the Minnesota–Oregon multi-state network, with mixed issuing-body participation from health departments, fire services, and state purchasing offices.